Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butadiene SCHEMBL2765003 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL2766280 | 0.77 | KDM4E (0.38) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL5029515 | 0.73 | KDM4E (0.44) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL2765827 | 0.71 | KDM4E (0.38) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL2767113 | 0.69 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL31010376 | 0.65 | KDM4E (0.36) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL2765963 | 0.64 | KDM4E (0.37) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 | |
| SCHEMBL2766782 | 0.64 | LMNA (0.36) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2766635 | 0.62 | CYP19A1 (0.37) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31010265 | 0.61 | EPHX2 (0.42) | ALDH1A1MEN1KMT2AKDM4EHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266911-B1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-6881802-B2 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | ALDH1A1 3572/4885MEN1 632/4885KMT2A 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.